SV

Street Verdict

Analyst Scorecard

A record of what Sumeet Bagadia said publicly, with the source. Not advice.

“Recommends buying Concord Biotech for intraday trading at ₹2,237.25, targeting ₹2,394 with a stop loss at ₹2,159, driven by positive market sentiment and a breakout strategy.”

Sumeet Bagadia’s track record (trackable calls only): 1528 graded calls · 95% CI 32–37%

Concord Biotech LtdBullishCalled 05 Feb 2025Graded 11 Feb 2025
Verdict:MISS

How this call is judged

A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate.

Entry: ₹2,237.25, as stated.

Target ₹2,394, stop ₹2,159, as stated.

Window: 30 days, the time frame the call states ("intraday").

The stop ₹2,159 was reached on a close before the target ₹2,394. Miss.

The grader’s working: R3 TRADE_SETUP: entered ₹2235.2 on 2025-02-10 (stated entry ₹2237.25, DIP_LIMIT entry, filled); stop ₹2159 breached at close ₹2131.2 on 2025-02-11. Window 30 days — rule H1: the quote says "intraday" (a one-day claim, judged over 30 days; MISS if neither level is reached).

Tracking Concord Biotech Ltd since this call

1-year tracking window
Read the original articleSee Sumeet Bagadia’s full track record